Cargando…

Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter

Adverse side effects of cancer agents are of great concern in the context of childhood tumors where they can reduce the quality of life in young patients and cause life-long adverse effects. Synergistic drug combinations can lessen potential toxic side effects through lower dosing and simultaneously...

Descripción completa

Detalles Bibliográficos
Autores principales:	Radic-Sarikas, Branka, Halasz, Melinda, Huber, Kilian V. M., Winter, Georg E., Tsafou, Kalliopi P., Papamarkou, Theodore, Brunak, Søren, Kolch, Walter, Superti-Furga, Giulio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465103/ https://www.ncbi.nlm.nih.gov/pubmed/28596528 http://dx.doi.org/10.1038/s41598-017-03129-6

Ejemplares similares

Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers
por: Tsafou, Kalliopi, et al.
Publicado: (2018)

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance
por: Voges, Yvonne, et al.
Publicado: (2016)

Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines
por: Michaelis, Martin, et al.
Publicado: (2020)

Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells
por: Gholizadeh, Shima, et al.
Publicado: (2018)

YM155 Induces EGFR Suppression in Pancreatic Cancer Cells
por: Na, Young-Soon, et al.
Publicado: (2012)

Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension
por: Blanco, Isabel, et al.
Publicado: (2023)

YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells
por: ONG, Siew Mei, et al.
Publicado: (2019)

Epigenetic Changes at the Birc5 Promoter Induced by YM155 in Synovial Sarcoma
por: Mika, Aleksander, et al.
Publicado: (2019)

YM155 Inhibits NleB and SseK Arginine Glycosyltransferase Activity
por: Zhu, Congrui, et al.
Publicado: (2021)

The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma
por: Xia, Hongping, et al.
Publicado: (2015)

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer
por: McCorkle, J. Robert, et al.
Publicado: (2021)

The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis
por: Kovar, Heinrich, et al.
Publicado: (2020)

A Chemo-Genomic Approach Identifies Diverse Epigenetic Therapeutic Vulnerabilities in MYCN-Amplified Neuroblastoma
por: Krstic, Aleksandar, et al.
Publicado: (2021)

Effect of Sepatronium Bromide (YM-155) on DNA Double-Strand Breaks Repair in Cancer Cells
por: Majera, Dusana, et al.
Publicado: (2020)

Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment
por: Vay, Christian, et al.
Publicado: (2021)

Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells
por: Tao, Yan-Fang, et al.
Publicado: (2012)

YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway
por: Chang, Bill H, et al.
Publicado: (2015)

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1
por: Wagner, Verena, et al.
Publicado: (2014)

Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels
por: Sim, Mei Yi, et al.
Publicado: (2017)

Dioxonaphthoimidazoliums AB1 and YM155 disrupt phosphorylation of p50 in the NF-κB pathway
por: Ho, Si Han Sherman, et al.
Publicado: (2016)

Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1– Mediated Gemcitabine Chemoresistance
por: Bai, Zhiqing, et al.
Publicado: (2022)

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
por: Iwasa, T, et al.
Publicado: (2010)

Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
por: Nakamura, Naoto, et al.
Publicado: (2012)

Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues
por: Cheng, Xiao Jiao, et al.
Publicado: (2016)

YM155 decreases radiation-induced invasion and reverses epithelial–mesenchymal transition by targeting STAT3 in glioblastoma
por: Zhang, Xin, et al.
Publicado: (2018)

Structure-Activity Relationship Analysis of YM155 for Inducing Selective Cell Death of Human Pluripotent Stem Cells
por: Go, Young-Hyun, et al.
Publicado: (2019)

YM155 sensitizes HeLa cells to TRAIL-mediated apoptosis via cFLIP and survivin downregulation
por: Chandrasekaran, Arun Pandian, et al.
Publicado: (2020)

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib
por: Redaelli, Sara, et al.
Publicado: (2015)

YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network
por: Véquaud, Eloïse, et al.
Publicado: (2015)

Correction to: YM155 decreases radiation-induced invasion and reverses epithelial–mesenchymal transition by targeting STAT3 in glioblastoma
por: Zhang, Xin, et al.
Publicado: (2021)

Ym155 localizes to the mitochondria leading to mitochondria dysfunction and activation of AMPK that inhibits BMP signaling in lung cancer cells
por: Mondal, Arindam, et al.
Publicado: (2022)

YM155, specific survivin inhibitor, can enhance artesunate-induced cytotoxicity in HCT116 colon cancer cells
por: Kim, Eui Tae, et al.
Publicado: (2020)

Molecular Characterization of Auxin Efflux Carrier- ABCB1 in hexaploid wheat
por: Mohan, Amita, et al.
Publicado: (2019)

Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS
por: MINODA, MASAYA, et al.
Publicado: (2015)

Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK
por: Danielpour, David, et al.
Publicado: (2019)

Remarkable Synergy When Combining EZH2 Inhibitors with YM155 Is H3K27me3-Independent
por: Yang, Jun, et al.
Publicado: (2022)

Zooming in on Long Non-Coding RNAs in Ewing Sarcoma Pathogenesis
por: Aryee, Dave N. T., et al.
Publicado: (2022)

TAT-IL-24-KDEL-induced apoptosis is inhibited by survivin but restored by the small molecular survivin inhibitor, YM155, in cancer cells
por: Zhang, Jian, et al.
Publicado: (2016)

YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting
por: Michaelis, Martin, et al.
Publicado: (2020)

Hypoxia represses early responses of prostate and renal cancer cells to YM155 independent of HIF-1α and HIF-2α
por: Danielpour, David, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6lnpaqrrq1c1a77clrbt6h42f9